2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Unknown
1
Recruiting
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Plasma cell
2
Conditions
Leukemia, Myeloid, Acute
14
Myelodysplastic Syndromes
13
Precursor Cell Lymphoblastic Leukemia-Lymphoma
6
Leukemia, Myelomonocytic, Chronic
3
Neoplasm Metastasis
2
Multiple Myeloma
2
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2
Leukemia, Biphenotypic, Acute
2
Leukemia
2
Hodgkin Disease
2
Hematologic Neoplasms
2
Uveal Melanoma
1
Shwachman-Diamond Syndrome
1
Sarcoma, Ewing
1
Recurrence
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasm, Residual
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Melanoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Leukemia, Prolymphocytic
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myeloid, Accelerated Phase
1
Interventions
Dexamethasone
808
Bortezomib
446
Lenalidomide
430
Cyclophosphamide
336
Melphalan
250
Calcium Dobesilate
236
daratumumab
217
pomalidomide
201
carfilzomib
181
fludarabine phosphate
131
Thalidomide
121
fludarabine
118
Peripheral Blood Stem Cell Transplantation
117
Filgrastim
111
ixazomib
85
Mycophenolic Acid
85
Granulocyte Colony-Stimulating Factor
84
Busulfan
83
Whole-Body Irradiation
80
Tacrolimus
75
dexamethasone acetate
74
Cyclosporine
67
Prednisone
64
dexamethasone 21-phosphate
63
isatuximab
62
elotuzumab
60
auricularum
57
Antilymphocyte Serum
55
belantamab mafodotin
54
Etoposide
52
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Multiple Myeloma
×
treosulfan
×
Clear all
NCT05636787
2024-07-08
TreoMel
Insel Gruppe AG, University Hospital Bern
Phase 2
Recruiting
120 enrolled
NCT01010243
2012-05-30
MM03
University of Regensburg
Phase 1/2
Unknown
54 enrolled